CarsonAllaria Wealth Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

CarsonAllaria Wealth Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-190	Closed	-$3.42K	–	372
2023 Q2	$3.42K	Hold	190	–	–	﹤0.01%	290
2023 Q1	$3.05K	Hold	190	–	–	﹤0.01%	282
2022 Q4	$3K	Hold	190	–	–	﹤0.01%	260
2022 Q3	$4K	Hold	190	–	–	﹤0.01%	237
2022 Q2	$4K	Hold	190	–	–	﹤0.01%	241
2022 Q1	$4K	Hold	190	–	–	﹤0.01%	259
2021 Q4	$5K	Buy	+190	New	+$4.68K	﹤0.01%	263

Other funds holding CRNX

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CarsonAllaria Wealth Management's CRNX Position: Q3 2023 in Review

CarsonAllaria Wealth Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 190 shares — an estimated $3.42K sold.

CarsonAllaria Wealth Management first reported a position in CRNX in Q4 2021 and held it in 7 quarters. The position peaked at $5K in Q4 2021. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

CarsonAllaria Wealth Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
CarsonAllaria Wealth Management sold 190 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $3.42K.
CarsonAllaria Wealth Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 7 quarters.
CarsonAllaria Wealth Management's Crinetics Pharmaceuticals position peaked at $5K in Q4 2021.
171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2023, filed 9 Nov 2023.